Medtronic SEC Filings

The Vanguard Group has updated its ownership disclosure for Medtronic PLC. The firm reports beneficial ownership of 130,949,305 shares of Medtronic common stock, representing 10.21% of the class. Vanguard reports no sole voting power over these shares, with shared voting power over 7,668,852 shares. It has sole dispositive power over 118,346,690 shares and shared dispositive power over 12,602,615 shares.

The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Medtronic. Vanguard indicates that its clients, including registered investment companies and other managed accounts, have the right to receive dividends or sale proceeds from these securities, and no single other person has an interest in more than 5% of the class.

Medtronic plc reported higher results for the quarter ended October 24, 2025. Net sales rose to $8,961 million from $8,403 million a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, with segment sales reaching $8,926 million. Net income attributable to Medtronic increased to $1,374 million from $1,270 million, and diluted earnings per share improved to $1.07 from $0.99.

For the first six months of fiscal 2026, net sales were $17,539 million versus $16,318 million, and net income attributable to Medtronic was $2,414 million compared with $2,312 million. Operating cash flow was $2,013 million, while the company continued returning cash via dividends of $1,820 million and share repurchases of $495 million. Medtronic reduced its Italian payback accrual by $39 million, recorded as a sales benefit, and recognized a $90 million fair value loss on its Mozarc Medical investment.

On the balance sheet, cash and cash equivalents stood at $1,282 million with $7,045 million in investments. Total assets were $91,346 million, total liabilities $42,489 million, and total equity $48,857 million. Long-term debt increased to $27,680 million, including new 2.950% notes due 2031 and 4.200% notes due 2046, and the company had $1.4 billion of commercial paper outstanding.

Medtronic plc (MDT) reported an insider transaction by its Chief Accounting Officer. On 11/20/2025, the officer disposed of 170 ordinary shares of Medtronic stock at a reported price of $0, which is consistent with a coded gift transaction. After this transaction, the officer beneficially owned 12,357 ordinary shares.

A footnote explains that this ownership total includes 99 shares acquired through dividend reinvestment since the prior report. The filing shows no derivative securities positions for this reporting person.

Medtronic plc executive vice president for Global Operations & Supply Chain reported multiple open-market sales of company ordinary shares. On 11/19/2025, the officer sold several blocks of Medtronic stock at prices around $102 per share, reducing but not eliminating their direct stake. Following these transactions, the officer directly owned 46,016 ordinary shares.

The reported holdings also include 323 shares acquired through dividend reinvestment and 96 shares acquired under Medtronic's Employee Stock Ownership Plan since the prior report, showing ongoing participation in company equity programs alongside the sales.

A Medtronic (MDT) shareholder filed a Form 144 notice to potentially sell 30,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an approximate aggregate market value of $3,058,452.26. The planned sale date listed is 11/19/2025. The shares come from multiple acquisitions between 2022 and 2025, including employee stock purchase plan buys funded with cash and restricted stock units that vested as compensation. The filing also notes that Medtronic has 1,282,685,882 shares of this class outstanding, giving context for the size of the potential sale relative to the overall share count.

Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026. On November 18, 2025, the company issued a press release with these results, which is included as Exhibit 99.1. The report also confirms Medtronic’s status as an Irish public limited company and lists its ordinary shares and various series of senior notes, with maturities ranging from 2027 to 2053, as being listed on the New York Stock Exchange.

Medtronic plc reported that Gregory L. Smith, Executive Vice President, Enterprise Operations, will retire from the company effective December 2, 2025 and plans to join a private equity‑held organization. The company states he will receive retirement treatment for outstanding equity as previously disclosed.

Under those equity terms, unvested stock options will accelerate, while restricted stock units (RSUs) and performance stock units (PSUs) will continue to vest in line with the applicable award agreements filed with the SEC.

Medtronic plc reported the results of its Annual General Meeting held on October 16, 2025. Shareholders approved amendments to the company’s Memorandum and Articles of Association, including changes to Article 177 to allow the Board to capitalize certain non-distributable reserves to create distributable reserves and updates to the advance notice provisions. They also approved a capital reduction to create distributable reserves under Irish law.

All twelve director nominees were elected and shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 and authorized the Board, through the Audit Committee, to set auditor remuneration. Shareholders renewed the Board’s authority to issue shares and to opt out of pre-emption rights under Irish law, and authorized the company and its subsidiaries to make overseas market purchases of ordinary shares. At the record date, 1,282,616,011 ordinary shares were outstanding; 1,109,198,321 were represented at the meeting, constituting a quorum.